Laboratoire Of Pathologie Experimentale

Liège, Belgium

Laboratoire Of Pathologie Experimentale

Liège, Belgium
SEARCH FILTERS
Time filter
Source Type

Maisonial-Besset A.,French Institute of Health and Medical Research | Maisonial-Besset A.,University of Auvergne | Witkowski T.,French Institute of Health and Medical Research | Witkowski T.,University of Auvergne | And 40 more authors.
Oncotarget | Year: 2017

Tetraspanin 8 (TSPAN8) overexpression is correlated with poor prognosis in human colorectal cancer (CRC). A murine mAb Ts29.2 specific for human TSPAN8 provided significant efficiency for immunotherapy in CRC pre-clinical models. We therefore evaluate the feasability of targeting TSPAN8 in CRC with radiolabeled Ts29.2. Staining of tissue micro-arrays with Ts29.2 revealed that TSPAN8 espression was restricted to a few human healthy tissues. DOTA-Ts29.2 was radiolabeled with 111In or 177Lu with radiochemical purities > 95%, specific activity ranging from 300 to 600 MBq/mg, and radioimmunoreactive fractions > 80%. The biodistribution of [111In]DOTA-Ts29.2 in nude mice bearing HT29 or SW480 CRC xenografts showed a high specificity of tumor localization with high tumor/blood ratios (HT29: 4.3; SW480-TSPAN8: 3.9 at 72h and 120h post injection respectively). Tumor-specific absorbed dose calculations for [177Lu]DOTA-Ts29.2 was 1.89 Gy/MBq, establishing the feasibility of using radioimmunotherapy of CRC with this radiolabeled antibody. A significant inhibition of tumor growth in HT29 tumor-bearing mice treated with [177Lu]DOTA-Ts29.2 was observed compared to control groups. Ex vivo experiments revealed specific DNA double strand breaks associated with cell apoptosis in [177Lu]DOTA-Ts29.2 treated tumors compared to controls. Overall, we provide a proof-of-concept for the use of [111In/177Lu] DOTA-Ts29.2 that specifically target in vivo aggressive TSPAN8-positive cells in CRC.


Telliam G.,University Paris - Sud | Feraud O.,University Paris - Sud | Griscelli F.,University Paris - Sud | Opolon P.,Laboratoire Of Pathologie Experimentale | And 3 more authors.
Stem Cell Research | Year: 2016

Chronic myeloid leukemia (CML) is a clonal malignancy initiated by the occurrence of a t (9;22) translocation, generating Ph1 chromosome and BCR-ABL oncogene in a primitive hematopoietic stem cell (HSC). The resistance of HSC to targeted therapies using tyrosine kinase inhibitors remains a major obstacle towards the cure. We have generated an iPSC line from a patient with CML using leukemic CD34 + cells cryopreserved at diagnosis. Ph1 + CML cells were reprogrammed by non-integrative viral transduction. These iPSCs harboured Ph1 chromosome and expressed pluripotency hallmarks as well as BCR-ABL. Teratoma assays revealed normal differentiation after injection in immunodeficient mice. © 2016 Helmholtz Zentrum München


Bennaceur-Griscelli A.,French Institute of Health and Medical Research | Bennaceur-Griscelli A.,University Paris - Sud | Hadoux J.,French Institute of Health and Medical Research | Feraud O.,French Institute of Health and Medical Research | And 11 more authors.
Stem Cell Research | Year: 2017

Multiple Endocrine Neoplasia Type 2B (MEN2B) is a cancer-predisposing syndrome that affects patients with germline RET mutations. The clinical spectrum of the syndrome includes medullary thyroid carcinoma (MTC) and pheochromocytoma. Currently, there is no satisfactory model recapitulating all the features of the disease especially at the level of stem cells. We generated induced pluripotent stem cells (iPSCs) from a patient with RET mutation at codon 918 who developed pheochromocytoma and MTC. These iPSC had normal karyotype, harboured the RETM918T mutation and expressed pluripotency hallmarks. A comprehensive pathological assessment of teratoma was performed after injection in immunodeficient mice. © 2017


Hadoux J.,University Paris - Sud | Feraud O.,University Paris - Sud | Griscelli F.,University Paris - Sud | Opolon P.,Laboratoire Of Pathologie Experimentale | And 5 more authors.
Stem Cell Research | Year: 2016

Multiple Endocrine Neoplasia Type 2A (MEN2A) is a cancer-predisposing syndrome that affects patients with germline RET mutations. The clinical spectrum of the syndrome includes medullary thyroid carcinoma (MTC), pheochromocytoma, hyperparathyroidism and cutaneous lichen amyloidosis (CLA) and/or Hirschsprung disease in some variants. Currently, there is no satisfactory animal model recapitulating all the features of the disease especially at the level of stem cells. We generated induced pluripotent stem cells (iPSCs) from a patient with RET mutation at codon 634 who developed pheochromocytoma and MTC. RETC634Y-mutated cells were reprogrammed by non-integrative viral transduction. These iPSCs had normal karyotype, harboured the RETC634Y mutation and expressed pluripotency hallmarks as well as RET. A comprehensive pathological assessment of teratoma was performed after injection in immunodeficient mice. © 2016 The Authors.


PubMed | Laboratoire Of Pathologie Experimentale, Gustave Roussy and University Paris - Sud
Type: Journal Article | Journal: Stem cell research | Year: 2016

Multiple Endocrine Neoplasia Type 2A (MEN2A) is a cancer-predisposing syndrome that affects patients with germline RET mutations. The clinical spectrum of the syndrome includes medullary thyroid carcinoma (MTC), pheochromocytoma, hyperparathyroidism and cutaneous lichen amyloidosis (CLA) and/or Hirschsprung disease in some variants. Currently, there is no satisfactory animal model recapitulating all the features of the disease especially at the level of stem cells. We generated induced pluripotent stem cells (iPSCs) from a patient with RET mutation at codon 634 who developed pheochromocytoma and MTC. RET

Loading Laboratoire Of Pathologie Experimentale collaborators
Loading Laboratoire Of Pathologie Experimentale collaborators